Zomedica Corp (AMEX:ZOM) finished Thursday with a subtraction of $0.0 to close at $0.17, an upside of 1.82 percent. An average of 2,535,160 shares of common stock have been traded in the last five days. There was a gain of $0.0019 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 3,212,795 shares traded, while the 50-day average volume stands at 3,688,878.
ZOM stock has decreased by -9.34% in the last month. The company shares reached their 1-month lowest point of $0.1608 on 09/15/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $0.15 and a high of $0.34 in 52 weeks. It has reached a new high 6 times so far this year and achieved 3.07% or $0.0050 in price. In spite of this, the price is down -49.85% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Zomedica Corp (ZOM) stock’s beta is 1.00. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 7.34, the price-to-book (PB) ratio at 0.63.
Financial Health
The quick ratio of Zomedica Corp for the three months ended June 29 was 18.86, and the current ratio was 19.37, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.01 for the quarter ending June 29. Zomedica Corp’s EBITDA margin for the year ending June 29 is -94.46%, while its operating margin for the same period stands at -115.81%. Its gross profit as reported stood at $13.65 million compared to revenue of $18.93 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$5.25 million in the quarter, while revenues of -$6.39 million were shrunk -0.38%. The analyst consensus anticipated Zomedica Corp’s latest quarter earnings to come in at $0 per share, but it turned out to be $0. For the quarter, EBITDA amounted to -$5.87 million. Shareholders own equity worth $979.95 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Zomedica Corp (ZOM) price momentum. RSI 9-day as of the close on 28 September was 42.50%, suggesting the stock is Neutral, with historical volatility in this time frame at 52.61%.
As of today, ZOM’s price is $0.1672 +1.14% or $0.0019 from its 5-day moving average. ZOM is currently trading -8.94% lower than its 20-day SMA and -19.62% lower than its 100-day SMA. However, the stock’s current price level is -20.00% below the SMA50 and -11.58% below the SMA200.
The stochastic %K and %D were 31.71% and 28.95%, respectively, and the average true range (ATR) was 0.0070. With the 14-day stochastic at 33.96% and the average true range at 0.0073, the RSI (14) stands at 41.13%. The stock has reached -0.0015 on the 9-day MACD Oscillator while the 14-day reading was at -0.0030.
Analyst Ratings
Dawson James launched coverage on Zomedica Corp (AMEX: ZOM) in its analyst report released on January 06, 2023. The firm assigned the stock a Buy rating.
What is ZOM’s price target for the next 12 months?
Analysts predict a range of price targets between $0.44 and $0.44, with a median target of $0.44. Taking a look at these predictions, the average price target given by analysts for Zomedica Corp (ZOM) stock is $0.44.
